Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

NCT03649841 | Terminated Phase 2 Results DMC FDA Drug

• 4 other identifiers: RG1001784NCI-2018-015489938P50CA097186
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer. Hormone therapy such as antiandrogen therapy may fight prostate cancer by blocking the production and interfering with the action of hormones. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Neutron radiation therapy uses high energy neutrons to kill tumor cells and shrink tumors. It is not yet known whether antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy may work better in treating patients with prostate cancer.

Conditions

Castration-Sensitive Prostate Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8

Keywords

Prostate Cancer

Outcome Measures

Primary Outcomes (1)

• Percent Change in Peripheral Blood Effector T-cells (CCR7-/CD45RO)

  Percent change in peripheral blood effector T-cells will be calculated by measuring the difference of the percent peripheral blood effector T-cells for each patient between two time points: pre-treatment and post-treatment (3 months after start of ADT, which is also 1 month post-radiation in the radiation arm). Unpaired two-sample t-test or Wilcoxon rank-sum test, depending on distribution of the percent change, will be used to test the null hypothesis that the percent change in peripheral blood effector T-cells is equal between the two arms.

  Baseline to 3 months after start of antiandrogen therapy (ADT)

Secondary Outcomes (2)

• Rate of Undetectable Prostate Specific Antigen (PSA) (< 0.2)

  At 6 months after start of abiraterone acetate

• Incidence of Adverse Events

  Up to 6 months

Study Arms (2)

Arm I (ADT, abiraterone, prednisone)

ACTIVE COMPARATOR

Patients receive ADT per standard of care. Beginning 2 months after start of ADT, patients also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.

Drug: Antiandrogen Therapy; Drug: Abiraterone Acetate; Drug: Prednisone

Arm II (ADT, abiraterone, prednisone, radiation therapy)

EXPERIMENTAL

Patients receive ADT, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting ADT and within 1 week of starting abiraterone acetate, patients also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.

Drug: Antiandrogen Therapy; Drug: Abiraterone Acetate; Drug: Prednisone; Radiation: Radiation Therapy

Interventions

Antiandrogen Therapy DRUG

Undergo ADT

Also known as: ADT, Androgen Deprivation Therapy, Androgen Deprivation Therapy (ADT), Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy

Arm I (ADT, abiraterone, prednisone); Arm II (ADT, abiraterone, prednisone, radiation therapy)

Abiraterone Acetate DRUG

Undergo Abiraterone Acetate Treatment SOC

Also known as: 17-(3-Pyridyl)-5,16-androstadien-3beta-acetate, 154229-18-2, Yonsa, Zytiga

Arm I (ADT, abiraterone, prednisone); Arm II (ADT, abiraterone, prednisone, radiation therapy)

Prednisone DRUG

Undergo Prednisone Treatment SOC

Also known as: 10023, Delta 1-Cortisone

Arm I (ADT, abiraterone, prednisone); Arm II (ADT, abiraterone, prednisone, radiation therapy)

Radiation Therapy RADIATION

Undergo neutron radiation therapy

Also known as: Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, NOS, Radiotherapeutics, radiotherapy, RT, ENERGY TYPE

Arm II (ADT, abiraterone, prednisone, radiation therapy)

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pathologically proven (either histologic or cytologic) diagnosis of prostate adenocarcinoma with \< 50% neuroendocrine differentiation or small cell histology.
• At least one site of nodal or distant metastatic disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or a bony metastasis that is evaluable on both computed tomography (CT) and bone scan.
• No prior orchiectomy.
• No androgen deprivation therapy such as treatment with antiandrogens, luteinizing hormone-releasing hormone (LHRH) agonists or antagonists for at least one year prior to trial enrollment, and testosterone must be inside normal range prior to trial enrollment if there is prior history of ADT.
• No other systemic anti-cancer therapy for at least 1-year prior to enrollment.
• Prior prostate-directed therapies such as prostatectomy or cryotherapy are allowed.
• Prior radiation treatments are allowed (prostate or metastatic sites) but must have been completed at least 3 months prior to starting ADT for this trial.
• White blood cell (WBC) \> 3000/mm\^3.
• Absolute neutrophil count (ANC) \> 1000/mm\^3.
• Platelets \> 100,000/mm\^3.
• Creatinine \< 1.5 institutional upper limit of normal (ULN) or calculated creatinine clearance \> 30 ml/min.
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin \< 3 x institutional ULN (unless patient has documented Gilbert's syndrome).
• No steroids for at least 2 weeks prior to enrollment, and patient must not be expected to require steroids during the study period, other than the typical low dose steroid that is given with abiraterone (typically prednisone or prednisolone at 5 mg twice daily).
• Zubrod performance status 0-2.
• Patient must sign study specific informed consent prior to study entry.

You may not qualify if:

• Other illnesses with a life expectancy of less than 6 months, including but not limited to unstable angina, symptomatic congestive heart failure, cardiac arrhythmias.
• Psychological or social issues that would prevent patients from informed consent or complying with study requirements.
• Subject has a history of unexplained loss of consciousness or transient ischemic attack within 12 months of treatment start.
• Individuals on active treatment for a different cancer are excluded. Individuals with a history of other malignancies are eligible if they are deemed by the investigator to be at low risk for recurrence of that malignancy.
• Known brain metastasis.
• Known allergies, hypersensitivity, or intolerance to abiraterone or prednisone.
• Prior ADT less than a year, or greater than two months, prior to trial enrollment or prior ADT with testosterone less than normal.
• There is a potential drug interaction when abiraterone is concomitantly used with a CYP2D6 substrate narrow therapeutic index (e.g., thioridazine, dextromethorphan), or strong CYP3A4 inhibitors (e.g., atazanavir, erythromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) or strong inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine). Caution should be used when patients are on one of these drugs.
• Patients with a history of pituitary or adrenal dysfunction, active or symptomatic viral hepatitis, human immunodeficiency virus (HIV), or chronic liver disease are not eligible.
• Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/prednisolone once daily.

Sponsors & Collaborators

• University of Washington: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Androgen Antagonists; Abiraterone Acetate; Prednisone; Radiotherapy; Radiation

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Pharmacologic Actions; Chemical Actions and Uses; Androstenes; Androstanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnanes; Therapeutics; Physical Phenomena

Limitations and Caveats

Early termination due to poor patient accrual leading to small numbers of subjects analyzed.

Results Point of Contact

• Title: Dr. Jing Zeng
• Organization: University of Washington

jzeng13@uw.edu

2065984110

Study Officials

• Jing Zeng

  University of Washington

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 22, 2018
• First Posted: August 28, 2018
• Study Start: June 29, 2020
• Primary Completion: September 1, 2022
• Study Completion: February 1, 2023
• Last Updated: October 26, 2023
• Results First Posted: October 26, 2023

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)